Lupin: Look beyond the short-term concerns

Strong product approval rate in the US and mega launches on exclusivity basis are key positives

News flow around US product approvals and launches remain strong for Lupin. In the past few days, it has received one approval for launch on exclusivity for a Bowel preparation kit. Also, it has launched a scalp treatment and a dermatology drug in the US. Besides, it has also entered into a marketing agreement in Japan to exclusively distribute and promote extended-release tablets of schizophrenia drug. The tie-up in Japan will boost revenue from the world’s second largest drug market, which contributes 10 per cent to Lupin’s top line and the launch of Bowel kit can garner $30 million during